Vero Biosciences

verobioscience.com →

-60%

est. 2Y upside i

HealthcareSeries B

Rank

#1381

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Low

Vero Biosciences presents a moderate upside opportunity with a 70% expected return over a 2-year horizon, but this comes with a higher risk profile.

Last updated: March 10, 2026

Bull (30%)+300%

Vero Biosciences successfully navigates regulatory hurdles and achieves widespread consumer adoption of its at-home tests, establishing market leadership in biological age assessment. Strategic partnerships and successful clinical validation of interventions drive revenue to over $200M by 2028, justifying a $400M+ valuation at a premium multiple, well above the assumed current $100M.

Base (20%)+75%

Vero Biosciences achieves moderate market penetration, primarily through early adopters and partnerships, but faces challenges in scaling and competition from established players. Revenue reaches approximately $70M by 2028, leading to an acquisition or next funding round at a $175M valuation, offering a modest return on the assumed current $100M.

Bear (50%)-70%

Vero Biosciences encounters significant regulatory delays or strong incumbent competition, hindering market entry and adoption. High capital intensity leads to a down round or failure to secure sufficient future funding, resulting in a valuation of $30M or less, severely impacting common stock value given the existing liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $27M in liquidation preferences ahead of common stock, representing 27% of the assumed $100M valuation.

Dilution Risk

high

As a Series B company with very high capital intensity, Vero Biosciences will likely require multiple additional funding rounds, leading to significant future dilution for common shareholders.

Secondary Liquidity

none

Given the early stage (Series B), there is currently no active secondary market or tender offers for employee equity.

Questions to Ask at the Interview

Strategic questions based on Vero Biosciences's data — designed to show you've done your homework.

  • 1

    “How does Vero Biosciences plan to navigate the high regulatory barriers for both its diagnostic tests and proposed interventions, particularly given the 2-year horizon for market impact and the need for rigorous clinical validation?”

  • 2

    “With a TAM of $3.1B and a $200 per test revenue model, what is the projected path to achieving significant market penetration and scaling revenue to justify a multi-billion dollar valuation, especially considering the high capital intensity?”

  • 3

    “Given the Series B funding and the current preference stack, what is the company's strategy for managing future dilution and providing liquidity opportunities for employees, particularly within the next 2-5 years?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.